Key Details
Price
$0.96Annual ROE
-61.18%Beta
1.12Events Calendar
Next earnings date:
Mar 20, 2025Recent quarterly earnings:
Dec 10, 2024Recent annual earnings:
Mar 20, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
UTRECHT, The Netherlands and PHILADELPHIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, reported financial results for the third quarter ended September 30, 2024 and announced a strategic pipeline reprioritization.
Are you looking for stocks to buy with low price tags?
LAVA Therapeutics (LVTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference.
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a virtual fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference which will be available on Monday, September 11, 2023 at 7:00 am ET.
LAVA Therapeutics N.V. (LVTX) came out with a quarterly loss of $0.48 per share in line with the Zacks Consensus Estimate.
Lava (LVTX) falls 10% due to its decision to discontinue the study on LAVA-051, which is being evaluated for multiple hematological tumors. The company shifts focus to LAVA-1207 in the prostate cancer study.
FAQ
- What is the ticker symbol for LAVA Therapeutics NV?
- Does LAVA Therapeutics NV pay dividends?
- What sector is LAVA Therapeutics NV in?
- What industry is LAVA Therapeutics NV in?
- What country is LAVA Therapeutics NV based in?
- When did LAVA Therapeutics NV go public?
- Is LAVA Therapeutics NV in the S&P 500?
- Is LAVA Therapeutics NV in the NASDAQ 100?
- Is LAVA Therapeutics NV in the Dow Jones?
- When was LAVA Therapeutics NV's last earnings report?
- When does LAVA Therapeutics NV report earnings?
- Should I buy LAVA Therapeutics NV stock now?